Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2159-2169

  Zhau, Haiyen E ^a,b   He, Hui ^a   Wang, Christopher Y ^a   Zayzafoon, Majd ^c   Morrissey, Colm ^d   Vessella, Robert L ^d   Marshall, Fray F ^a   Chung, Leland W K ^a,b   Wang, Ruoxiang ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UNCOUPLING PROTEIN 1;

APOPTOSIS; ARTICLE; BONE MARROW MESENCHYMAL STEM CELL; BONE METASTASIS; BROWN ADIPOSE TISSUE; CANCER CELL; CANCER GROWTH; CELL DIFFERENTIATION; CELL LINEAGE; CELL SPECIFICITY; CELL STRAIN LNCAP; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MESENCHYMAL STEM CELL; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ADIPOCYTES; APOPTOSIS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL LINEAGE; CULTURE MEDIA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; ION CHANNELS; MALE; MESENCHYMAL STEM CELLS; MITOCHONDRIAL PROTEINS; NEOPLASTIC STEM CELLS; OSTEOBLASTS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS;

EID: 79954619522     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2523     Document Type: Article

References (43)

1. Alison MR, Islam S. Attributes of adult stem cells. J Pathol 2009;217:144-60.
2. Lam JS, Reiter RE. Stem cells in prostate and prostate cancer development. Urol Oncol 2006;24:131-40. (Pubitemid 43340170)
3. Collins AT, Maitland NJ. Prostate cancer stem cells. Eur J Cancer 2006;42:1213-8. (Pubitemid 43795097)
4. Kasper S. Exploring the origins of the normal prostate and prostate cancer stem cell. Stem Cell Rev 2008;4:193-201.
5. Kasper S. Stem cells: The root of prostate cancer? J Cell Physiol 2008;216:332-6. (Pubitemid 351898459)
6. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004;117:3539-45. (Pubitemid 39206394)
7. Brown MD, Gilmore PE, Hart CA, Samuel JD, Ramani VA, George NJ, et al. Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. Prostate 2007;67:1384-96. (Pubitemid 47435786)
8. Goodyear SM, Amatangelo MD, Stearns ME. Dysplasia of human prostate CD133 (hi) sub-population in NOD-SCIDS is blocked by c-myc anti-sense. Prostate 2009;69:689-98.
9. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R, et al. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog 2007;46:1-14. (Pubitemid 46095228)
10. Signoretti S, Loda M. Prostate stem cells: from development to cancer. Semin Cancer Biol 2007;17:219-24. (Pubitemid 46413076)
11. Brubaker KD, Vessella RL, Brown LG, Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003;56:13-22. (Pubitemid 36613151)
12. Knerr K, Ackermann K, Neidhart T, Pyerin W. Bone metastasis: osteoblasts affect growth and adhesion regulons in prostate tumor cells and provoke osteomimicry. Int J Cancer 2004;111:152-9. (Pubitemid 38859297)
13. Huang WC, Xie Z, Konaka H, Sodek J, Zhau HE, Chung LW. Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res 2005;65:2303-13. (Pubitemid 40490140)
14. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001;47:212-21. (Pubitemid 32378373)
15. Noth U, Osyczka AM, Tuli R, Hickok NJ, Danielson KG, Tuan RS. Multilineage mesenchymal differentiation potential of human trabecular bone-derived cells. J Orthop Res 2002;20:1060-9.
16. Wang R, Xu J, Saramaki O, Visakorpi T, Sutherland WM, Zhou J, et al. PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res 2004;64:1589-94. (Pubitemid 38428676)
17. Hausman GJ. Techniques for studying adipocytes. Stain Technol 1981;56:149-54. (Pubitemid 11059336)
18. Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, Multani A, et al. Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 2006;66:1664-73. (Pubitemid 44646357)
19. Wang R, Xu J, Mabjeesh N, Zhu G, Zhou J, Amin M, et al. PrLZ is expressed in normal prostate development and in human prostate cancer progression. Clin Cancer Res 2007;13:6040-8. (Pubitemid 350075060)
20. Wang R, Zhang L, Yin D, Mufson RA, Shi Y. Protein kinase C regulates Fas (CD95/APO-1) expression. J Immunol 1998;161:2201-7. (Pubitemid 28397030)
21. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003;34:646-53. (Pubitemid 36875509)
22. Nechad M, Kuusela P, Carneheim C, Bjorntorp P, Nedergaard J, Cannon B. Development of brown fat cells in monolayer culture. I. Morphological and biochemical distinction from white fat cells in culture. Exp Cell Res 1983;149:105-18. (Pubitemid 14209609)
23. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999;39:246-61. (Pubitemid 29244499)
24. Kubo H, Gardner TA, Wada Y, Koeneman KS, Gotoh A, Yang L, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003;14:227-41. (Pubitemid 36423442)
25. Nedergaard J, Petrovic N, Lindgren EM, Jacobsson A, Cannon B. PPARgamma in the control of brown adipocyte differentiation. Biochim Biophys Acta 2005;1740:293-304. (Pubitemid 40803456)
26. Park KW, Halperin DS, Tontonoz P. Before they were fat: adipocyte progenitors. Cell Metab 2008;8:454-7.
27. Klingenspor M, Fromme T, Hughes DA. Jr, Manzke L, Polymeropoulos E, Riemann T, et al. An ancient look at UCP1. Biochim Biophys Acta 2008;1777:637-41.
28. Sieff CA. Hematopoietic cell proliferation and differentiation. Curr Opin Hematol 1994;1:310-20.
29. McKenna SL, Cotter TG. Functional aspects of apoptosis in hematopoiesis and consequences of failure. Adv Cancer Res 1997;71:121-64. (Pubitemid 27197758)
30. Metcalf D. Concise review: hematopoietic stem cells and tissue stem cells: current concepts and unanswered questions. Stem Cells 2007;25:2390-5. (Pubitemid 47582731)
31. Longenecker JP, Williams JF. A mechanism of tumourigenesis: retrodifferentiation and reontogeny in cancer and its clinical significance. Med J Aust 1977;2:237-9. (Pubitemid 8191669)
32. Uriel J. Cancer, retrodifferentiation, and the myth of Faust. Cancer Res 1976;36:4269-75.
33. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, et al. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineagederived metastatic sublines. Int J Cancer 1998;77:887-94. (Pubitemid 28378138)
34. Arechaga I, Ledesma A, Rial E. The mitochondrial uncoupling protein UCP1: a gated pore. IUBMB Life 2001;52:165-73. (Pubitemid 33731570)
35. Bing C, Brown M, King P, Collins P, Tisdale MJ, Williams G. Increased gene expression of brown fat uncoupling protein (UCP) 1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res 2000;60:2405-10. (Pubitemid 30262430)
36. Argiles JM, Busquets S, Lopez-Soriano FJ. The role of uncoupling proteins in pathophysiological states. Biochem Biophys Res Commun 2002;293:1145-52. (Pubitemid 34681061)
37. Hass R. Rejuvenation in distinct cell populations - What does it mean? Exp Gerontol 2009;44:634-8.
38. Gottardis MM, Lamph WW, Shalinsky DR, Wellstein A, Heyman RA. The efficacy of 9-cis retinoic acid in experimental models of cancer. Breast Cancer Res Treat 1996;38:85-96. (Pubitemid 26030116)
39. Bruserud O, Gjertsen BT. New strategies for the treatment of acute myelogenous leukemia: differentiation induction - present use and future possibilities. Stem Cells 2000;18:157-65. (Pubitemid 30341663)
40. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875-91.
41. Venkitaraman R, Thomas K, Huddart RA, Horwich A, Dearnaley DP, Parker CC. Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int 2008;101:440-3. (Pubitemid 351160930)
42. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000;37:431-502. (Pubitemid 32173442)
43. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, et al. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 2009;16:37-44.